MorphoSys AG Reports First Quarter 2023 Financial Results

Monjuvi U.S. net product sales of US$ 20.8 million (€ 19.4 million) for the first quarter of 2023 Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline

Related Keywords

Massachusetts ,United States ,Boston ,Planegg ,Bayern ,Germany ,Canada ,United Kingdom ,American ,Charlotte Lohmann ,Jean Paul Kress ,Thomas Biegi ,Lucinda Crabtree ,Monjuvi Minjuvi ,Julia Neugebauer ,Eamonn Nolan ,American Association For Cancer Research ,Janssen Biotech Inc ,Morphosys Group Key Figures ,Nasdaq ,Exchange Commission ,Drug Administration ,American Society Of Clinical Oncology ,Twitter ,Share Of Loss Associates ,Xencor Inc ,Linkedin ,Development Rd Expenses ,Chief Executive Officer ,Chief Financial Officer ,Management Board ,Chief Legal Officer ,Morphosy Management Board ,Events After ,First Quarter ,Data Highlight ,American Association ,Cancer Research ,Annual Meeting ,Clinical Oncology ,Net Loss ,Sys Group Key Figures ,Impairment Losses ,Equity Method ,Tax Benefit ,Net Profit ,Antibody Dependent Cell Mediated Cytotoxicity ,Antibody Dependent Cellular Phagocytosis ,Janssen Biotech ,Looking Statements ,Morphosy Annual Report ,Investor Relations ,Morphosys ,Reports ,First ,Quarter ,023 ,Financial ,Results ,